OBJECTIVES: V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) specifically designed for adults. It includes eight unique serotypes (15A, 15C [from de-O-Ac-15B], 16F, 23A, 23B, 24F, 31 and 35B) not covered by any currently licensed pneumococcal vaccine. According to 2019 data from Germany, the serotypes covered by V116 were responsible for approximately 80% of invasive pneumococcal disease (IPD) in individuals aged 50+, and the unique 8 serotypes were responsible for approximately 20%. This study estimates the potential health and economic impact of vaccination with V116 vs. PCV20 on IPD amongst adults aged 50+ in Germany.

METHODS: A Markov model estimated the lifetime IPD cases, IPD related deaths, and the associated direct medical costs (2023 Euro) among adults aged 50-59 and 60+ years vaccinating with V116 or PCV20. The same serotype specific vaccine effectiveness, and the same vaccine coverage rates were assumed for the two vaccines.

RESULTS: Using vaccine coverage rate of 12.5% for adults aged 50-59 years at-risk and high risk of PD, V116 prevented 101 IPD cases and 13 IPD deaths – 29% more than the 78 IPD cases and 10 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in ~€236,000 reduction in direct medical costs –higher than the ~€183,000 costs averted by PCV20.

Using vaccine coverage rate of 23.3% in adults aged 60+ years, V116 prevented 578 IPD cases and 109 IPD deaths – 42% more than the 408 IPD cases and 77 IPD deaths prevented by PCV20. The averted IPD cases from V116 vaccination resulted in ~€1.5 million reduction in direct medical costs –higher than the ~€1 million costs averted by PCV20.

CONCLUSIONS: V116 led to a greater reduction (compared to PCV20) of both the health and economic burden associated with IPD among adults aged 50+years in Germany